NYSE$AMRX
Amneal Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported strong Q2 2023 results, driven by generics growth and AvKARE expansion, and raised full year 2023 guidance.
Amneal Pharmaceuticals, Inc. reported net revenue of $599 million for Q2 2023, a 7% increase compared to Q2 2022. GAAP net income was $12 million, with diluted EPS of $0.08. The company raised its full year 2023 guidance, expecting continued growth across its diversified portfolio.
- Net revenue increased by 7% to $599 million compared to the second quarter of 2022.
- Net income attributable to Amneal Pharmaceuticals, Inc. was $12 million, a significant improvement from the net loss of $121 million in the second quarter of 2022.
- Adjusted EBITDA increased by 9% to $146 million compared to the second quarter of 2022.
- The company raised its full year 2023 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS.
Headline financials
Revenue & EPS history
Amneal · Revenue · Quarterly
$599M
Revenue by segment
Amneal · $599M total across 3 segments · Q2 2023
- Affordable Medicines$374M+2.4%62.4%
- AvKARE$128M+31.7%21.4%
- Specialty$97M-0.0%16.2%
Forward guidance
The Company is raising its previously provided full year 2023 guidance.
Tailwinds
- Net revenue $2.30 billion - $2.40 billion
- Adjusted EBITDA $525 million - $540 million
- Adjusted diluted EPS $0.45 - $0.55
- Operating cash flow $220 million - $250 million
- Capital expenditures $50 million - $60 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.6%
Avg return
Earnings day
-3.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
54%
20 / 37 earnings
Positive
+36.6%
Q2 2023
Best reaction
-23.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -7.6% | +0.9% | |
| Q4 2025 | -4.6% | -8.2% | -18.2% | |
| Q3 2025 | -4.1% | +8.8% | +20.0% | |
| Q1 2025 | +3.0% | -6.7% | -5.4% | |
| Q4 2024 | +3.5% | +7.0% | -1.2% | |
| Q3 2024 | +6.9% | +4.9% | -1.9% | |
| Q2 2024 | +12.9% | +9.6% | +21.9% | |
| Q1 2024 | +7.1% | +6.1% | +7.6% | |
| Q4 2023 | -2.2% | -3.8% | +9.8% | |
| Q3 2023 | -3.6% | +0.2% | +11.4% | |
| Q2 2023 | +36.6% | +25.9% | +25.6% | |
| Q1 2023 | +9.8% | -3.3% | +38.6% | |
| Q4 2022 | -8.1% | -15.8% | -33.5% | |
| Q3 2022 | +13.0% | +8.2% | +16.8% | |
| Q2 2022 | -9.5% | -9.2% | -36.4% | |
| Q1 2022 | -11.5% | -22.2% | -13.0% | |
| Q4 2021 | -7.0% | -12.4% | -3.4% | |
| Q3 2021 | -12.5% | -9.8% | -29.0% | |
| Q2 2021 | +4.5% | +4.9% | +6.6% | |
| Q1 2021 | -8.1% | -8.0% | -5.5% | |
| Q4 2020 | +5.9% | +0.0% | +40.1% | |
| Q3 2020 | -15.0% | -15.6% | -14.6% | |
| Q2 2020 | -16.3% | -19.9% | -30.7% | |
| Q1 2020 | +20.3% | +16.1% | +42.5% | |
| Q4 2019 | -20.4% | -16.4% | -37.0% | |
| Q3 2019 | -23.0% | -23.0% | +7.0% | |
| Q2 2019 | -8.0% | -10.5% | -18.5% | |
| Q1 2019 | -20.7% | -31.0% | -41.8% | |
| Q4 2018 | +8.4% | +2.0% | +13.8% | |
| Q3 2018 | +5.1% | +4.6% | -9.1% | |
| Q2 2018 | +0.6% | +9.8% | +19.4% | |
| Q1 2018 | +1.5% | +13.3% | +30.2% | |
| Q4 2017 | +4.4% | — | — | |
| Q3 2017 | +5.9% | — | — | |
| Q2 2017 | +1.5% | — | — | |
| Q1 2017 | -3.2% | — | — | |
| Q4 2016 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro